WA-VIRTUOZZO
13.10.2021 13:02:12 CEST | Business Wire | Press release
Virtuozzo , a global leader in high-efficiency virtualization and hyperconverged software solutions, today announced its collaboration with DT Technology Group has accelerated DT’s transition from a leading telco to a leading digital platform enabler. Through the use of Virtuozzo Hybrid Infrastructure , DT has deployed a Public Cloud as well as new revenue streams via DevOps services—all while reducing its total cost of ownership by 30 percent.
Increasingly, companies seek to leverage digital solutions to transform their businesses. Simultaneously, SmartCity projects show no signs of slowing down. However, the continued growth of 5G connectivity and IoT applications brings with it new infrastructure design challenges—integration of AI computing, Cloud Native applications, GPU computing, application modernization, and DevOps resources. The supporting network infrastructure must be robust enough to scale with the demand while the software development ecosystem around it must be mature enough to enable enterprises as well as small- to medium-sized companies to leverage the technology trends for business gain.
Drawing on its ICT system integration and telecom roots, DT sought to address both needs by building an enterprise-grade and 5G-ready infrastructure as well as establishing a team of skilled digital software developers. In the late 2010’s, the company launched its Cloud platform and digital software solutions suite via partnerships with a hyperscaler and proprietary virtualization solutions provider, though quickly sought to replace them… and did with a single partner: Virtuozzo.
“We have a unique market opportunity. We understand the infrastructure requirements behind carrier grade platforms and are leveraging this expertise to build seamless, elastic enterprise-grade digital platforms,” said Tolga Dinçer, CEO, DT Technology Group. “Our initial partner choices, however, limited what we could deliver to customers as they were complicated to use, inflexible, and quite expensive. Virtuozzo Hybrid Infrastructure solved all of those problems out of the box.”
A Public Cloud for Modern Times
DT uses the OpenStack-based Virtuozzo Hybrid Infrastructure to host a robust 5G-enabled infrastructure supporting Public Cloud, Edge data centers, and OnPrem needs. The Cloud infrastructure scales easily and notably taps into local data centers to satisfy data sovereignty requirements. Further, its inherent capabilities driven by Virtuozzo’s hyperconverged system include support for various advanced solutions—from graphics-rich VDI services to compute-heavy, AI-dependent big data analytics.
A Digital Platform Partner for the DevOps Community
To help businesses capitalize on its robust infrastructure, DT also uses Virtuozzo’s software to deliver digital solutions. This offering includes consultative services as well as digital platform development—such as microservices architecture design—for cross-industry customers, and depends heavily on Virtuozzo Hybrid Infrastructure’s core features:
- Security and business continuity
- Production-ready Kubernetes environment and tools
- Flexible licensing models (PAYG pricing)
- Immediate scalability, up or down
- Storge-as-a-Service
- Hardware vendor agnostic
“Virtuozzo is purpose-built to help companies like DT shift their and their customers’ business models from capex to opex, helping reduce costs while gaining the benefits of hyperconverged, Cloud-driven digital transformation,” said Alex Fine, Virtuozzo CEO. “We’re seeing increased adoption of our technology by savvy service providers striving to deliver alternative Cloud services: services that compete with those of hyperscalers in diversity, performance and capabilities, but are simpler, more flexible, and far more cost-efficient to use. To that end, DT is optimizing Virtuozzo Hybrid Infrastructure to an incredible extent. We’re excited to see what they’ve accomplished to date and are proud to be a part of their continued journey.”
About DT Technology Group
Headquartered in Istanbul, DT Technology Group (www.dt.net.tr ) is an international digital platform enabler servicing Turkey and other locations worldwide. Since its 2006 inception, DT has evolved from being an ICT systems integrator to a telco responsible for thousands of installations of carrier network infrastructure for 2G through to 5G networks. In 2018, the company packaged its experience to create an enterprise-grade, 5G-ready multiregional Public Cloud offering.
About Virtuozzo
Virtuozzo (www.virtuozzo.com ) is a leading, global provider of hybrid virtualization, storage, and cloud enablement software solutions. The Company's software-defined, hyperconverged self-service platform and resource management capabilities enable hosting and service providers to provide end-customers with public and private cloud services. Virtuozzo is an industry pioneer who developed the first commercially available container technology 21 years ago. The Company provides software solutions and services to over 750 service providers, ISVs, and enterprises worldwide to enable hundreds of thousands of virtual environments, running mission-critical cloud workloads. A significant force in the open-source community, Virtuozzo sponsors and/or is a contributor to numerous open-source projects including KVM, Docker, OpenStack, OpenVZ, CRIU, and the Linux kernel.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211013005219/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom